1.	Phase III Efficacy and Safety Trial of Toremifene vs Tamoxifen in Postmenopausal/Perimenopausal Patients with Metastatic Breast Cancer (Summary Last Modified 08/90) Phase: Phase III Type: Treatment Status: Closed Age: peri/postmenopausal Sponsor: Protocol IDs: GUMC-9989, NCI-V89-0180
2.	Phase III Efficacy and Safety Trial of Toremifene vs Tamoxifen in Postmenopausal/Perimenopausal Patients with Metastatic Breast Cancer (Summary Last Modified 11/91) Phase: Phase III Type: Treatment Status: Closed Age: post/perimenopausal Sponsor: Protocol IDs: AECM-8805150, NCI-V89-0202
3.	Phase III Efficacy and Safety Trial of Toremifene vs Tamoxifen in Postmenopausal/Perimenopausal Patients with Metastatic Breast Cancer (Summary Last Modified 01/90) Phase: Phase III Type: Treatment Status: Closed Age: post/perimenopausal Sponsor: Protocol IDs: TCSC-092006-999, NCI-V89-0043
4.	Phase III Trial of the Efficacy and Safety of Toremifene vs Tamoxifen in Postmenopausal and Perimenopausal Patients with Metastatic Breast Cancer (Summary Last Modified 05/90) Phase: Phase III Type: Treatment Status: Completed Age: postmenopausal Sponsor: Protocol IDs: YALE-HIC-5026, NCI-V89-0229
5.	Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer Phase: Phase III Type: Treatment Status: Completed Age: under 71 Sponsor: Other Protocol IDs: CDR0000078385, IBCSG-12-93, EU-93015, NCI-F93-0010, NCT00002529
6.	Phase III Randomized Study of Adjuvant Anthracycline/Cyclophosphamide and Cyclophosphamide/Methotrexate/Fluorouracil with vs without a 16-Week Treatment-Free Interval Between Regimens and with Subsequent Tamoxifen vs Toremifene in Peri- and Postmenopausal Women with Node-Positive Breast Cancer Unsuitable for Endocrine Therapy Alone Phase: Phase III Type: Treatment Status: Closed Age: under 71 Sponsor: Protocol IDs: IBCSG-14-93, EU-93017, NCI-F93-0012
7.	Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: Biomed 777-CLP-29, NCT00044291
8.	Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia) Phase: Phase III Type: Prevention Status: Completed Age: 30 and over Sponsor: Pharmaceutical / Industry Protocol IDs: G300104, NCT00106691
9.	Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy Phase: Phase III Type: Supportive care Status: Completed Age: 50 and over Sponsor: Pharmaceutical / Industry Protocol IDs: G300203, NCT00129142
10.	Phase II Study of Toremifene in Patients With Desmoid Tumors (Summary Last Modified 07/2001). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: Other Protocol IDs: LGH-1011, NCI-V91-0211, NCT00002595
11.	Phase II Randomized Study of Interferon Alfa with or without Toremifene for Completely Resected Stage II or III Melanoma (Summary Last Modified 08/1999) Phase: Phase II Type: Treatment Status: Closed Age: guardian's consent or over 18 Sponsor: Other Protocol IDs: UCHSC-COMIRB-96044, NCI-V96-0827
12.	Phase II Study of Toremifene plus Cisplatin in Metastatic non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CHNMC-IRB-95061, LAC-USC-94A041-CC, UCD-95143, NCI-V96-1032
13.	Toremifene in Treating Patients With Ovarian Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000067029, GWCC-7096, NCI-V99-1540, NCT00003865
14.	Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention, Treatment Status: Completed Age: Over 18 Sponsor: NCI, Other Protocol IDs: CDR0000068708, PCI-00-105, PCI-N01-CN-75018, NCI-P01-0181, NCT00020735
15.	Phase II Study of Toremifene in Patients with Inoperable Stage III/IV Malignant Melanoma (Summary Last Modified 02/90) Phase: Phase II Type: Treatment Status: Closed Age: any age Sponsor: Protocol IDs: EORTC-18891
16.	Phase II Study of Toremifene in Peri- and Postmenopausal Patients with Advanced Breast Cancer Refractory to Tamoxifen (Summary Last Modified 01/90) Phase: Phase II Type: Treatment Status: Closed Age: peri/postmenopausal Sponsor: Protocol IDs: YALE-HIC-5138, NCI-V89-0231
17.	A Phase II Study of Toremifene in Patients with Metastatic ER-Negative and PgR-Negative Breast Cancer (Summary Last Modified 07/91) Phase: Phase II Type: Treatment Status: Closed Age: post/perimenopausal Sponsor: NCI Protocol IDs: CLB-8945, CALGB-8945